The treatment, called Ofev, slows the rate of decline in pulmonary function in adults with the rare lung condition.The FDA granted approval of Ofev to treat the disease to Boehringer Ingelheim.
Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis.
Read the full report here.
More articles on pharmacy:
Civica Rx says it isn’t afraid of competition
Cigna rolls out plan to fully cover expensive gene therapies
Rutgers to close 3 on-campus pharmacies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
